FDA regulatory consultants in a strategy session

FDA Regulatory Consulting

FDA Regulatory Consultant

Senior FDA regulatory consultants for pharmaceutical, biotech and medical device companies. Strategy, submissions, pre-submission meetings, inspection readiness and US Agent services — from one dedicated team with presence in the US and Australia.

FDA · TGA · EMA

Regulatory agencies navigated

10+

Years of FDA experience

US + Australia

Dual-market presence

Senior-led

Every engagement

Why TPC for FDA work

One FDA consulting team across the US and Australia

Trans-Pacific Compliance provides FDA regulatory consulting for pharmaceutical, biotech and medical device companies at every stage of development — from pre-IND strategy through to post-approval lifecycle management.

Our senior consultants have direct, hands-on experience with FDA submissions across multiple therapeutic categories, including small molecules, biologics, generics and medical devices. We manage the FDA relationship so your internal team can focus on the science.

Because we also hold deep TGA expertise, US-based companies entering Australia and Australian companies seeking FDA clearance work with one consistent team — not two separate firms with no line of sight between them.

Talk to an FDA consultant
FDA regulatory strategy planning session

FDA Services

End-to-end FDA regulatory support

From first strategy meeting to post-approval compliance — we cover every milestone of the FDA regulatory pathway.

Regulatory Strategy & Pathway Planning

Every FDA programme begins with the right strategy. We assess your compound or device, your clinical data and your commercial objectives to define the most efficient approval pathway — NDA, ANDA, 505(b)(2), BLA, IND or device premarket submission.

  • Application type selection (NDA, ANDA, 505(b)(2), BLA)
  • Target product profile development
  • Pre-clinical and clinical study design guidance
  • Regulatory gap analysis and risk mapping
  • Multi-jurisdictional pathway planning (FDA + TGA/EMA)
Learn more

FDA Pre-Submission Meetings

Pre-IND, End-of-Phase-2 and pre-NDA/BLA meetings are among the most valuable FDA interactions a sponsor can have. We prepare your briefing package, sharpen your questions, and support you through the meeting — turning agency feedback into a clear action plan.

  • Pre-IND meeting preparation and briefing package
  • End-of-Phase-2 (EOP2) meeting strategy
  • Pre-NDA/BLA meeting preparation
  • Question development and position statements
  • Post-meeting analysis and follow-up planning
Learn more

IND, NDA, BLA & ANDA Submissions

A well-prepared submission is the single most important factor in achieving timely approval. We manage the full lifecycle of your FDA submissions — from initial planning and gap analysis through authoring, quality review and eCTD publishing.

  • IND, NDA, ANDA, 505(b)(2), BLA, DMF preparation
  • eCTD publishing and SPL labeling
  • Cross-module consistency review
  • Pre-submission quality check against agency guidance
  • Agency information request (IR/AIR) responses
Learn more

510(k), PMA & Medical Device Submissions

FDA medical device regulation is a discipline in its own right. We support device sponsors through classification, premarket submissions and post-market compliance — from 510(k) and De Novo through to PMA applications and combination products.

  • Device classification and regulatory pathway selection
  • 510(k) substantial equivalence submissions
  • De Novo and PMA application support
  • Q-Sub (pre-submission) meeting preparation
  • Post-market reporting and MDR obligations
Learn more

FDA Inspection Readiness & GMP Compliance

An FDA inspection tests your documentation, your people and your quality culture. We prepare pharmaceutical manufacturers and sponsors for FDA inspections through structured readiness programmes — identifying gaps, remediating them, and ensuring your team responds confidently.

  • Pre-inspection documentation audit
  • Mock FDA inspections
  • Back-room team training and preparation
  • SOP review and gap remediation
  • GMP audit response and CAPA development
Learn more

FDA Liaison & U.S. Agent Services

Foreign manufacturers distributing products in the US must designate a US Agent for FDA. We act as your primary FDA contact — managing correspondence, establishment registration, product listings and all formal agency interactions on your behalf.

  • US Agent designation (21 CFR Part 1)
  • FDA establishment registration and product listing
  • Agency correspondence management
  • Information request (IR/AIR) response management
  • Inspection notification and liaison support
Learn more

How we work

From first call to FDA approval

01

Free consultation

We discuss your product, target market and development stage. No obligation — this call is about understanding your situation.

02

Regulatory assessment

We assess your programme, identify the right FDA pathway and surface any gaps that need addressing before submission.

03

Strategy and plan

We build a regulatory plan aligned to your timeline and budget — covering application type, agency meeting strategy and submission milestones.

04

Execution and submission

Our consultants prepare documents, manage agency interactions and coordinate across your CMC, clinical and nonclinical teams.

05

Review and approval

We manage the FDA review — responding to information requests, preparing for meetings, and tracking the submission through to decision.

Your FDA team

Senior consultants — not junior coordinators

Every FDA engagement at Trans-Pacific Compliance is led by Rani Sabhavat or Leah Thompson — senior consultants with hands-on experience across FDA submissions, pre-submission meetings, GMP audits and device regulatory pathways. You will not be handed to a coordinator after your first call.

  • FDA, EMEA & KDMF submissions
  • CTD / eCTD dossier preparation
  • 510(k), De Novo & PMA pathways
  • GMP compliance — 21 CFR Parts 210, 211, 820
  • 19+ years pharmaceutical industry experience
  • TGA A1 GMP compliance rating achieved
Meet the team
Trans-Pacific Compliance FDA regulatory consulting team

FAQ

FDA regulatory consulting — common questions

General information only — not legal or regulatory advice.

What does an FDA regulatory consultant do?

An FDA regulatory consultant guides pharmaceutical, biotech and medical device companies through the FDA approval process — from defining the right application type and preparing briefing packages for pre-submission meetings, to authoring and submitting INDs, NDAs, BLAs, ANDAs and device applications, responding to agency information requests, and preparing for FDA inspections.

When should I engage an FDA consultant?

The earlier the better. Engaging a consultant at the pre-IND or pre-clinical stage allows you to build a development programme that anticipates FDA expectations, choose the right application pathway, and avoid expensive course-corrections later. That said, we also step in mid-programme or at the submission stage when needed.

Can you support both US and Australian submissions?

Yes — supporting both FDA and TGA pathways from one team is central to what we do. We coordinate US and Australian work so your submissions move forward in step and development data supports both filings where possible.

Do you handle medical devices as well as pharmaceuticals?

Yes. We support 510(k), De Novo, PMA and Q-Sub submissions for FDA, and device ARTG registration for TGA. Device and drug-device combination products are both within our scope.

How is a free consultation structured?

It is an initial conversation — typically 30 minutes — where we learn about your product, your target market and your timeline, and outline how we could help. There is no obligation and no fee.

Start here

Talk to an FDA regulatory consultant today

Whether you are preparing your first IND, navigating a pre-NDA meeting, or need ongoing FDA compliance support — book a free consultation and we will outline the right path forward for your product.